Long-Term Liabilities: The sum of all non-current liabilities.
AgomAb Therapeutics NV (AGMB) had Long-Term Liabilities of 4.77M for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
| Balance Sheet Financials | |
137.17M |
|
0.77M |
|
35.71M |
|
173.90M |
|
21.03M |
|
1.14M |
|
|
Long-Term Liabilities |
4.77M |
25.80M |
|
148.10M |
|
115.61M |
|
148.10M |
|
-- |
|
| Cash Flow Statement Financials | |
-58.54M |
|
-37.34M |
|
-0.38M |
|
193.99M |
|
97.77M |
|
-96.22M |
|
-- |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|